/

Batteries & E-Mobility

/

Exelixis

Exelixis

Exelixis

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

Alameda, California

·

Since 1994

Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.

Exelixis

Verified Nov 2026

AT A GLANCE

Founded

1994

Headquarters

United States flag

Alameda, California

Employees

1,000-5,000

Ownership

Exelixis at a glance

Revenue

$1-5B

Est. band

Employees

1,000-5,000

Founded

1994

Headquarters

Alameda, California

Industries

Automotive

Electric Vehicles

Medical

Industrial Equipment

Overview

Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.

At a glance

Attribute

Detail

Founded

1994

Headquarters

Alameda, California

Employees

1,000-5,000

Revenue

$1-5B (estimated)

Primary capability

Batteries & E-Mobility

What Exelixis makes

The company manufactures multikinase inhibitor therapies targeting receptor tyrosine kinases to inhibit tumor growth in difficult-to-treat cancers.

Latest developments

Facilities

Exelixis is headquartered in Alameda, California. Public sources also reference these locations:

Company details

Exelixis collaborates with major pharmaceutical companies to expand the commercial reach and clinical application of its cancer medicines. Exelixis was founded in 1994, has an estimated 1,000-5,000 employees, and is headquartered in Alameda, California.

Frequently asked questions

What does Exelixis make?

Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.

Where is Exelixis headquartered?

Exelixis is headquartered in Alameda, California (1851 Harbor Bay Parkway, Alameda, California, 94502).

When was Exelixis founded?

Exelixis was founded in 1994.

How big is Exelixis?

Exelixis has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Alameda, California (HQ)Headquarters · United States
Alameda, California (HQ)1851 Harbor Bay Parkway, Alameda, California, 94502, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.